Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jun;25(6):719–724. doi: 10.1111/j.1365-2125.1988.tb05258.x

Lisinopril pharmacokinetics in chronic renal failure.

B Jackson 1, R B Cubela 1, E L Conway 1, C I Johnston 1
PMCID: PMC1386449  PMID: 2849471

Abstract

1. Lisinopril, a new orally active angiotensin converting enzyme inhibitor, was given to eight patients with stable chronic renal failure, in a dose of 5 mg 24 h-1 for 1 week. Creatinine clearance of the subjects ranged from 0.22 to 1.11 ml s-1. Lisinopril pharmacokinetics were studied over 8 days. 2. There was a close correlation between creatinine clearance and total 'area under the curve' over the 8 days of study (r = -0.88, P less than 0.05), and plateau lisinopril concentration and creatinine clearance (r = -0.77, P less than 0.05). 3. Serum angiotensin converting enzyme activity was inhibited in proportion to log serum lisinopril concentration (r = -0.99, P less than 0.001). Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1. 4. Creatinine clearance was unaltered by treatment. Serum potassium rose to over 5 mmol 1-1 in four patients, without adverse clinical effect.

Full text

PDF
719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson S., Meyer T. W., Rennke H. G., Brenner B. M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985 Aug;76(2):612–619. doi: 10.1172/JCI112013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Biollaz J., Burnier M., Turini G. A., Brunner D. B., Porchet M., Gomez H. J., Jones K. H., Ferber F., Abrams W. B., Gavras H. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981 May;29(5):665–670. doi: 10.1038/clpt.1981.92. [DOI] [PubMed] [Google Scholar]
  3. Curtis J. J., Luke R. G., Whelchel J. D., Diethelm A. G., Jones P., Dustan H. P. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med. 1983 Feb 17;308(7):377–381. doi: 10.1056/NEJM198302173080707. [DOI] [PubMed] [Google Scholar]
  4. Drummer O. H., Worland P. J., Jarrott B. Tissue distribution of captopril, reducible captopril conjugates and S-methylcaptopril in the rat. Biochem Pharmacol. 1983 May 15;32(10):1563–1568. doi: 10.1016/0006-2952(83)90328-3. [DOI] [PubMed] [Google Scholar]
  5. Edwards C. R., Padfield P. L. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet. 1985 Jan 5;1(8419):30–34. doi: 10.1016/s0140-6736(85)90975-4. [DOI] [PubMed] [Google Scholar]
  6. Hirakata H., Onoyama K., Hori K., Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol. 1986 Jul;26(1):27–32. [PubMed] [Google Scholar]
  7. Hirakata H., Onoyama K., Iseki K., Kumagai H., Fujimi S., Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol. 1984;4(6):355–360. doi: 10.1159/000166851. [DOI] [PubMed] [Google Scholar]
  8. Hricik D. E., Browning P. J., Kopelman R., Goorno W. E., Madias N. E., Dzau V. J. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983 Feb 17;308(7):373–376. doi: 10.1056/NEJM198302173080706. [DOI] [PubMed] [Google Scholar]
  9. Jackson B., Cubela R., Johnston C. I. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension. J Hypertens. 1984 Aug;2(4):371–377. [PubMed] [Google Scholar]
  10. Jackson B., Matthews P. G., McGrath B. P., Johnston C. I. Angiotensin converting enzyme inhibition in renovascular hypertension: frequency of reversible renal failure. Lancet. 1984 Jan 28;1(8370):225–226. doi: 10.1016/s0140-6736(84)92149-4. [DOI] [PubMed] [Google Scholar]
  11. Johnston C. I., Arnolda L., Hiwatari M. Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Drugs. 1984 Mar;27(3):271–277. doi: 10.2165/00003495-198427030-00006. [DOI] [PubMed] [Google Scholar]
  12. Johnston C. I., Jackson B., Cubela R., Larmour I., Arnolda L. Evaluation of angiotensin converting enzyme (ACE) in the pharmacokinetics and pharmacodynamics of ACE inhibitors. J Cardiovasc Pharmacol. 1986;8 (Suppl 1):S9–14. doi: 10.1097/00005344-198600081-00003. [DOI] [PubMed] [Google Scholar]
  13. Kripalani K. J., McKinstry D. N., Singhvi S. M., Willard D. A., Vukovich R. A., Migdalof B. H. Disposition of captopril in normal subjects. Clin Pharmacol Ther. 1980 May;27(5):636–641. doi: 10.1038/clpt.1980.90. [DOI] [PubMed] [Google Scholar]
  14. Larmour I., Jackson B., Cubela R., Johnston C. I. Enalapril (MK421) activation in man: importance of liver status. Br J Clin Pharmacol. 1985 May;19(5):701–704. doi: 10.1111/j.1365-2125.1985.tb02699.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Murphy B. F., Whitworth J. A., Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed) 1984 Mar 17;288(6420):844–845. doi: 10.1136/bmj.288.6420.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Taguma Y., Kitamoto Y., Futaki G., Ueda H., Monma H., Ishizaki M., Takahashi H., Sekino H., Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985 Dec 26;313(26):1617–1620. doi: 10.1056/NEJM198512263132601. [DOI] [PubMed] [Google Scholar]
  17. Todd P. A., Heel R. C. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986 Mar;31(3):198–248. doi: 10.2165/00003495-198631030-00002. [DOI] [PubMed] [Google Scholar]
  18. Ulm E. H., Hichens M., Gomez H. J., Till A. E., Hand E., Vassil T. C., Biollaz J., Brunner H. R., Schelling J. L. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357–362. doi: 10.1111/j.1365-2125.1982.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES